Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.

S E J van de BergPuck T PelzerA J van der LandE AbdrakhmanovaA Muhammad OziM AriasS Cook-ScaliseG DravnieceA GebhardS JunejaR HandayaniD KappelM KimerlingI KoppelaarS MalhotraB MyrzalievB NsaJ SugihartoN EngelC MulderS van den Hof

Published in: BMC public health (2021)

Acceptability and feasibility of the BPaL regimen is high among TB stakeholders in Indonesia, Kyrgyzstan, and Nigeria. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints.

Keyphrases

drug resistant
end stage renal disease
ejection fraction
multidrug resistant
newly diagnosed
chronic kidney disease
mycobacterium tuberculosis
healthcare
emergency department
prognostic factors
acinetobacter baumannii
patient reported outcomes
cystic fibrosis
pseudomonas aeruginosa
electronic health record